Chimerix To Cease Participation In Clinical Studies Of Ebola Drug

(RTTNews) - Biopharmaceutical Company Chimerix, Inc. (CMRX) said late Friday that it would terminate further participation in clinical studies of brincidofovir for Ebola Virus Disease or EVD citing the number of new cases of confirmed Ebola Virus Disease in Liberia has decreased significantly over the last several weeks. This includes a study in Liberia sponsored by the U.K.'s University of Oxford, which began in January.

The company specified that the decision was announced after discussions with the U.S. Food and Drug Administration. The company added that the decision to cease further study of brincidofovir in individuals with EVD does not impact the company's continued focus on advancing brincidofovir in pivotal studies of CMV prevention and for the treatment of adenovirus infection.